These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 28261655)

  • 1. Topical Application of a Galenical Formulation for the Management of Everolimus-Induced Mucositis in Patients with Metastatic Cancer: a Retrospective Study.
    Conforti S; Minardi S; Conforti L; Turano S; Bilotta S; Vilardo E; Palazzo S
    Oncol Ther; 2016; 4(2):275-286. PubMed ID: 28261655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
    Rugo HS; Seneviratne L; Beck JT; Glaspy JA; Peguero JA; Pluard TJ; Dhillon N; Hwang LC; Nangia C; Mayer IA; Meiller TF; Chambers MS; Sweetman RW; Sabo JR; Litton JK
    Lancet Oncol; 2017 May; 18(5):654-662. PubMed ID: 28314691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer.
    Chambers MS; Rugo HS; Litton JK; Meiller TF
    J Am Dent Assoc; 2018 Apr; 149(4):291-298. PubMed ID: 29439772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.
    Jones VE; McIntyre KJ; Paul D; Wilks ST; Ondreyco SM; Sedlacek S; Melnyk A; Oommen SP; Wang Y; Peck SR; O'Shaughnessy JA
    Oncologist; 2019 Sep; 24(9):1153-1158. PubMed ID: 30833486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer.
    Rugo HS
    Clin Breast Cancer; 2016 Feb; 16(1):18-22. PubMed ID: 26507507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral care and oral assessment guide in breast cancer patients receiving everolimus and exemestane: subanalysis of a randomized controlled trial (Oral Care-BC).
    Umeda M; Ota Y; Kashiwabara K; Hayashi N; Naito M; Yamashita T; Mukai H; Nakatsukasa K; Amemiya T; Watanabe KI; Hata H; Kikawa Y; Taniike N; Yamanaka T; Mitsunaga S; Nakagami K; Adachi M; Kondo N; Shibuya Y; Niikura N
    Ann Transl Med; 2021 Apr; 9(7):535. PubMed ID: 33987233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial.
    Porta C; Verzoni E; Zai S; Messina C; Ferrari V; Gri N; Procopio G
    Tumori; 2020 May; ():300891620915786. PubMed ID: 32364051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.
    Aapro M; Andre F; Blackwell K; Calvo E; Jahanzeb M; Papazisis K; Porta C; Pritchard K; Ravaud A
    Ann Oncol; 2014 Apr; 25(4):763-773. PubMed ID: 24667713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial.
    Royce M; Bachelot T; Villanueva C; Özgüroglu M; Azevedo SJ; Cruz FM; Debled M; Hegg R; Toyama T; Falkson C; Jeong J; Srimuninnimit V; Gradishar WJ; Arce C; Ridolfi A; Lin C; Cardoso F
    JAMA Oncol; 2018 Jul; 4(7):977-984. PubMed ID: 29566104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occurrence and characterization of everolimus adverse events during first and subsequent cycles in the treatment of metastatic breast cancer.
    Vargo CA; Berger MJ; Phillips G; Mrozek E
    Support Care Cancer; 2016 Jul; 24(7):2913-8. PubMed ID: 26847349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With Invasive Breast Cancer.
    Divers J; O'Shaughnessy J
    Clin J Oncol Nurs; 2015 Aug; 19(4):468-74. PubMed ID: 26207713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I Trial of Everolimus and Capecitabine in Metastatic HER2
    Vidal GA; Chen M; Sheth S; Svahn T; Guardino E
    Clin Breast Cancer; 2017 Oct; 17(6):418-426. PubMed ID: 28385537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.
    Lo Muzio L; Arena C; Troiano G; Villa A
    Oral Dis; 2018 Mar; 24(1-2):144-171. PubMed ID: 29480626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Everolimus in Daily Clinical Practice Focusing to Oral Mucosa Damage Issues - Single Oncology Centre Experience within the Course of the Year 2016].
    Vokurka S; Votavová M; Arnetová V; Korunková H; Svoboda T; Kulhánková J; Kališová K; Matějka VM; Fiala O; Fínek J
    Klin Onkol; 2017; 30(Supplementum1):195-197. PubMed ID: 28471205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer.
    Ng VC; Johnson JJ; Cuellar S
    J Oncol Pharm Pract; 2015 Dec; 21(6):433-42. PubMed ID: 24964967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer.
    Lolli C; Gallà V; Schepisi G; Barone D; Burgio SL; Maugeri A; Vertogen B; Amadori D; De Giorgi U
    Oncologist; 2017 Jul; 22(7):784-e74. PubMed ID: 28546463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer.
    Alvarez RH; Bechara RI; Naughton MJ; Adachi JA; Reuben JM
    Oncologist; 2018 Jun; 23(6):660-669. PubMed ID: 29487226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptome Sequencing Reveals the Mechanism behind Chemically Induced Oral Mucositis in a 3D Cell Culture Model.
    Lambros M; Moreno J; Fei Q; Parsa C; Orlando R; Van Haute L
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients.
    Martins F; de Oliveira MA; Wang Q; Sonis S; Gallottini M; George S; Treister N
    Oral Oncol; 2013 Apr; 49(4):293-8. PubMed ID: 23312237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II randomized trial of a non-steroidal mouth wash for prevention and treatment of stomatitis in women with hormone receptor positive breast cancer treated with everolimus.
    Peddi PF; Tetef M; Coluzzi P; Arzoo KK; Hu EH; Berkowitz MJ; Chan D; Moore D; Adams B; Wang X; Hurvitz SA
    Ther Adv Med Oncol; 2020; 12():1758835920967259. PubMed ID: 33299473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.